{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.4","upperLimit":"45.8","value":"40.0"}]}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.1","upperLimit":"26.8","value":"21.7"}]}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"295"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"OG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.","reportingStatus":"POSTED","timeFrame":"12 months and 24 months","title":"Percentage of Participants Who Continue to Receive Treatment at 12 Months and 24 Months After Start of Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}